Clinical Pharmacology in Gastroenterology: Development of New Forms of Treatment of Inflammatory Bowel Disease

References

• Hodgson H FJ. One disease or two?. Inflammatory bowel diseases. 2nd ed, R N Allan, M RB Keighley, J Alexander-Williams, C F Hawkins. Churchill Livingstone, London 1990; 121–6
   Google Scholar
• Brynskov J, Nielsen O H, Ahnefeldt-Rønne I, Bendtzen K. Review: Cytokines in inflammatory bowel disease. Scand J Gastroenterol 1992; 27: 897–906
   PubMed Web of Science ®Google Scholar
• Brynskov J. Review: cyclosporin for inflammatory bowel disease, mechanisms and possible actions. Scand J Gastroenterol 1993; 28: 849–57
   PubMed Web of Science ®Google Scholar
• Brynskov J. Cyclosporin in Crohn's disease. Therapeutic and pathogenetic implications [Thesis]. Lægeforeningens forlag, Copenhagen 1994
   Google Scholar
• Brynskov J, Nielsen O H, Ahnefeldt-Rønne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig Dis 1994; 12: 290–304
   PubMed Web of Science ®Google Scholar
• Present D H, Korelitz B I, Wisch N. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981–7
   PubMed Web of Science ®Google Scholar
• Khan A KA, Piris J, Truelove S C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; ii: 892–-5
   Google Scholar
• Rasmussen S N, Bondesen S, Hvidberg E F, et al. 5-aminosalicylic acid in a slow release preparation: bioavailability, plasma level and excretion in humans. Gastroenterology 1982; 83: 1062–70
   PubMed Web of Science ®Google Scholar
• Rasmussen S N, Binder V, Maier K, et al. Treatment of Crohn's disease with peroral 5-aminosalicylic acid. Gastroenterology 1983; 85: 1350–3
   PubMed Web of Science ®Google Scholar
• Nielsen O H, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 1983; 16: 738–40
   PubMed Web of Science ®Google Scholar
• Bondesen S, Tage-Jensen U, Jacobsen O, et al. 5-aminosalicylic acid in patients with ileo-rectal anastomosis. A comparison of the fate of sulphasalazine and Pentasa. Eur J Clin Pharmacol 1986; 31: 23–6
   PubMedGoogle Scholar
• Fallingborg J, Christensen L A, Ingeman-Nielsen M, et al. pH profile and regional transit times of the gut measured by a radiotelemetry device. Aliment Pharmacol Therap 1989; 3: 605–13
   PubMed Web of Science ®Google Scholar
• Fallingborg J, Christensen L A, Ingeman-Nielsen M, et al. Measurement of gastrointestinal pH, and regional transit times in normal children. J Pediatr Gastroenterol. Nütz 1990; 11: 211–4
   PubMed Web of Science ®Google Scholar
• Fallingborg J, Christensen L A, Ingeman-Nielsen M, et al. Gastrointestinal pH and transit times in healthy subjects with ileostomy. Aliment Pharmacol Therap 1990; 4: 247–53
   PubMed Web of Science ®Google Scholar
• Christensen L A, Fallingborg J, Abildgaard K, et al. Topical and systemic availability of 5-aminosalicylate: Comparisons of three controlled release preparations in man. Aliment Pharmacol Therap 1990; 4: 523–33
   PubMed Web of Science ®Google Scholar
• Christensen L A, Fallingborg J. Oroileal transit of 5-aminosalicylic acid. Gut 1994; 35: 287
   PubMedGoogle Scholar
• Christensen L A, Slot O, Sanchez G, et al. Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time. Br J Clin Pharmacol 1987; 23: 365–69
   PubMed Web of Science ®Google Scholar
• Kjærgaard N, Christensen L A, Lauritsen J G, et al. Effects of mesalazine substitution on salicylazo-sulfapyridine induced seminal abnormalities in men with ulcerative colitis. Scand J Gastroenterol 1989; 24: 891–96
   PubMed Web of Science ®Google Scholar
• Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for the treatment of active ulcerative colitis. Results of a controlled trial. Am J Gastroenterol 1993; 88: 1188–97
   PubMed Web of Science ®Google Scholar
• Mulder C JJ, Tytgat G NJ, Weterman I T, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988; 95: 1449–53
   PubMed Web of Science ®Google Scholar
• Rasmussen S N, Lauritsen K, Tage-Jensen U, et al. 5-aminosalicylic acid in the treatment of Crohn's disease: a 16 week double-blind, placebo-controlled multicenter study with Pentasa. Scand J Gastroenterol 1987; 22: 877–83
   PubMed Web of Science ®Google Scholar
• Singleton J W, Hanauer S B, Gitnick G L, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16 week trial. Gastroenterology 1993; 104: 1293–301
   PubMed Web of Science ®Google Scholar
• Gendre J P, Mary J Y, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. Gastroenterology 1993; 104: 435–39
   PubMed Web of Science ®Google Scholar
• Borel J F, Feurer C, Gubler H U, Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6: 468–75
   PubMedGoogle Scholar
• Borel J F, Feurer C, Magnée C, Stähelin H. Effect of the new antilymphocyte peptide cyclosporin A in animals. Immunology 1977; 32: 1017–25
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Cellular and molecular processes underlying immunoinflammation. Clinical impact of the monitoring of allergic inflammation, S Ahlstedt, P Mattson, J Thorell, P Venge. Academic Press, London 1991; 187–200
   Google Scholar
• Brynskov J, Tvede N. Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin. Gut 1990; 31: 795–9
   PubMed Web of Science ®Google Scholar
• Tvede N, Brynskov J. Interleukin-2 responses of blood mono-nuclear cells from patients with inflammatory bowel disease. APMIS 1991; 99: 759–64
   PubMed Web of Science ®Google Scholar
• Brynskov J, Tvede N, Andersen C B, Vilien M. Increased concentrations of interleukin 1β, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsies with active inflammatory bowel disease. Gut 1991; 33: 55–8
   Google Scholar
• Nielsen O H, Brynskov J. Soluble interleukin-2 receptors in ulcerative colitis. Med Inflam 1993; 2: 115–8
   PubMedGoogle Scholar
• Kirman I, Nielsen O H, Kjaersgaard E, Brynskov J. Interleukin-2 receptor alpha and beta chain expression by circulating alpha-beta and gamma-delta T cells in inflammatory bowel disease. Dig Dis Sci 1995; 40: 291–5
   PubMed Web of Science ®Google Scholar
• Schreiber S L, Crabtree G R. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136–42
   PubMedGoogle Scholar
• Brynskov J. The role of cyclosporine therapy in Crohn's disease. A review. Dig Dis 1991; 9: 236–44
   PubMedGoogle Scholar
• Brynskov J, Thomsen H, Levin Nielsen S. Renographic monitoring of renal function in patients with Crohn's disease treated with low dose cyclosporin: a controlled study. Br Med J 1990; 300: 1438–9
   PubMedGoogle Scholar
• Brynskov J, Freund L, Nørby Rasmussen S, et al. A placebocontrolled, double-blind, randomized trial of cyclosporine therapy in chronic active Crohn's disease. N Engl J Med 1989; 321: 845–50
   PubMed Web of Science ®Google Scholar
• Brynskov J, Freund F, Nørby Rasmussen S, et al. Final report on a placebo-controlled, double-blind, randomised, multicentre trial of cyclosporin treatment in active chronic Crohn's disease. Scand J Gastroenterol 1991; 26: 689–95
   PubMed Web of Science ®Google Scholar
• Jewell D P, Lennard-Jones J E. Oral Cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 1994; 6: 499–505, Cyclosporin Study Group of Great Britain and Ireland
   Web of Science ®Google Scholar
• Lichtiger S, Present D H, Kornbluth A, et al. Cyclosporine in ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841–5
   PubMed Web of Science ®Google Scholar
• Brynskov J, Freund L, Campanini M C, Kampmann J P. Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn's disease. Scand J Gastroenterol 1992; 27: 961–7
   PubMed Web of Science ®Google Scholar
• Actis G C, Ottobrelli A, Lagget M, et al. Intravenous cyclosporin (CY-A) for refractory ulcerative colitis (UC). A phase II study to reduce dose and toxicity. Gastroenterology 1994; 106(Suppl A642), [Abstract].
   Google Scholar
• Baert F, Hanauer S. CyA in severe steroid resistant UC: Long-term results of therapy. Gastroenterology 1994; 106(Suppl: A648), [Abstract].
   Google Scholar
• Sandborn W J, Wiesner R H, Tremaine W J, LaRusso N F. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1993; 34: 242–6
   PubMed Web of Science ®Google Scholar
• Sandborn W J, Tremaine W J, Schroeder K W, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994; 106: 1429–35
   PubMed Web of Science ®Google Scholar
• Brynskov J, Freund L, Østergaard Thomsen O. Treatment of refractory distal ulcerative colitis with cyclosporin retention enemas. Lancet 1989; l: 721–2
   Google Scholar
• Feagan B G, McDonald J WD, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330: 1846–51
   PubMed Web of Science ®Google Scholar
• McMillan M A. Clinical pharmacokinetics of cyclosporin. Pharmac Ther 1989; 42: 135–56
   PubMed Web of Science ®Google Scholar
• Grevel J, Nüesch E, Abisch E, Kutz K. Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. Eur J Clin Pharmacol 1986; 31: 211–6
   PubMed Web of Science ®Google Scholar
• Pedersen G, Brynskov J, Nielsen O H, Bendtzen K. Adhesion molecules: their role in inflammatory and neoplastic intestinal diseases. Dig Dis 1995; 13: 322–36
   PubMed Web of Science ®Google Scholar